Cost pressures turning pharma towards automation tech, says Zenith

By Dan Stanton

- Last updated on GMT


Related tags Industry

Increased cost pressures and a shift to biologics manufacturing are driving demand for automation technologies, says Zenith which is opening two offices in the US.

Cork, Ireland-based Zenith Technologies is expanding its US footprint, opening sites in sites in Oakland and San Diego, California to tap demand for its manufacturing support.

One of the highest growth areas for the firm is for its automation and workflow technologies which - according to US sales manager Mike Smith - is being driven by the shift from small to large molecule manufacturing in the region.

“Companies are now faced with converting existing facilities that were built to produce a particular drug into multi-product facilities,”​ he told this publication. “As a result, they need to implement more flexible automation systems and code.”

He added Zenith has so far benefited “significantly”​ due to its focus on the life science industry, and believes this will continue as drugmakers look to reduce their manufacturing costs in response to continued pressure to reduce their prices.

“This is creating the need for increased automation and MES [manufacturing execution systems] technologies” ​he continued, adding some of the key drivers have been “to increase capacity, multi-product manufacturing capability, increase in manufacturing yield consistency, decrease in batch record release time, equipment data management.”

Regulatory restrictions

Unlike other industries – automotive, for example – the pharma industry has been slow to install automation technologies in its processes. According to Smith, this is primarily due to the stringent regulatory requirements for drug manufacturing.

“Other industries do not have the added complexity of validated manufacturing and cleaning processes that are prevalent with pharmaceutical manufacturing. 

“Once a process is validated and documented, there may be significant implications for changes, there is also a heavy consideration towards patent expiry and how many batches are produced annually for various products.”

However, he continued, this is beginning to change.

“My feeling is that the FDA [US Food and Drug Administration] has made and is making significant strides regarding understanding automation philosophies when conducting site audits. The FDA would welcome more automation and less human involvement in most cases.”

Related news

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more